Temporary alleviation of MAPK by arbutin alleviates oxidative damage in the retina and ARPE-19 cells.

ABSTRACT: Dry age-related macular degeneration (AMD) is one of the main diseases that causes blindness in humans, and the number of cases is increasing yearly. However, effective treatments are unavailable, and arbutin (ARB) has been reported to have antioxidant, anti-inflammatory, and anti-aging effects in other age-related diseases. However, whether ARB can be used to treat dry AMD remains unknown. To explore the therapeutic potential and molecular mechanism of arbutin in the treatment of dry AMD. MTT assays, reactive oxygen species (ROS) production assays, flow cytometry assays, qPCR and western blotting were used to assess the impact of ARB on human RPECs induced by H₂O₂. A transcriptome sequencing assay was used to further explore how ARB acts on human RPECs treated with H

SUBMITTER: Wang L 

PROVIDER: S-EPMC11234033 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature